Top ▲


Disease ID:1231
Associated with:0 target
4 immuno-relevant ligands
Itching which can be associated with a number of disorders, commonly a symptom of seasonal allergies, hay fever, and eczema.


No target related data available for Pruritus


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Phase 2 clinical candidate for chronic pruritus (see NCT02909569).
Clinical Use: INCB039110 is being assessed in Phase 2 clinical trials as a potential treatment for indications such as rheumatoid arthritis (RA), post essential thrombocythemia myelofibrosis, chronic plaque psoriasis and non-small cell lung cancer (NSCLC). Phase 3 trials in chronic graft-versus-host disease are also underway. Click here to link to's complete list of INCB039110 studies. | View clinical data
Immuno Disease Comments: A sedating antihistamine that can be used to aid sleep in patients suffering from pruritus.
Clinical Use: The sedative action of hydroxyzine is used to treat anxiety and tension and is combined with other medications in anesthesia. Hydroxyzine may also be used to control nausea and vomiting and be used as an antihistamine to control pruritic symptoms. | View clinical data
Immuno Disease Comments: Approved drug for allergic pruritus.
Clinical Use: Used to treat allergic pruritis and motion sickness. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation. | View clinical data
Bioactivity Comments: We have been unable to find publicly available affinity data for this drug at its proposed human molecular target to substantiate its MMOA, and have therefore not tagged a primary drug target. Quantitative data at bovine targets is published in [2] which reports anti-histaminergic and anti-muscarinic effects of alimemazine in bovine brain. Alimemazine antagonises binding to bovine brain preparations (i.e. muscarinic acetylcholine receptor binding) with a Ki of 38nM [2]. | View biological activity
Immuno Disease Comments: Approved for relief of pruritic symptoms of corticosteroid-responsive skin conditions.
Clinical Use: Fludroxicortide is a topical corticosteroid drug. It is used to relieve inflammatory and pruritic symptoms of corticosteroid-responsive skin conditions. | View clinical data
Bioactivity Comments: The only available affinity data for this drug at the glucocorticoid receptor is contained in the DRUGMATRIX in vitro pharmacology data [1], which reports a Ki of 2.02nM. We do not map a primary drug target in this case. | View biological activity


Show »

1. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix,

2. Kubo N, Shirakawa O, Kuno T, Tanaka C. (1987) Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol, 43 (3): 277-82. [PMID:2884340]